Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
about
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasisLNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancerModeling somatic evolution in tumorigenesisSiah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumorsRNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivoIdentification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cellsThe PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancerEvolution of cooperation among tumor cellsKeystone symposium: the role of microenvironment in tumor induction and progression, Banff, Canada, 5-10 February 2005Internet-based Profiler system as integrative framework to support translational research.The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerClonal origin and spread of metastatic prostate cancerHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerPersistent androgen receptor addiction in castration-resistant prostate cancerEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerAndrogen receptor and prostate cancer stem cells: biological mechanisms and clinical implicationsDistinct genetic alterations in small cell carcinoma from different anatomic sitesThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceChemotherapy options in castration-resistant prostate cancerUsing circulating tumor cells to inform on prostate cancer biology and clinical utilityβ-Adrenergic Receptor Signaling in Prostate CancerThe TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cellsDetection of patient subgroups with differential expression in omics data: a comprehensive comparison of univariate measuresLow-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new boneMinimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE)Metastasis: a therapeutic target for cancer.Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceAnnotating STEAP1 regulation in prostate cancer with 89Zr immuno-PETDown regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell lineCharacterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.Pro-neural transcription factors as cancer markers.Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancerDAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis
P2860
Q21093318-A96EF1A0-6529-4D62-9AFD-4787D1EA9D38Q21202034-E6E262E0-B2EE-4EFF-8A40-E1D51D5AF321Q21563511-0E771A4D-605A-41E9-A8B8-CD7300A905D9Q24337932-3EB85B4A-7FD3-4A13-BF72-AB9E921D5B22Q24539093-C623A93E-3403-4B33-A369-871406C2BB26Q24546102-93316BC8-6168-44C5-A54B-2CBF8228F591Q24625643-A79B2AED-E81A-4DE6-AC8D-5DF0CD87FE42Q24650647-7109F394-A1E1-48E4-B987-49FB16D081A4Q24671009-ACA79A0A-545B-4E69-8561-44414D0398F3Q24810275-89B2ECC0-2C14-4F99-AE2B-8B62D0024227Q25257221-FA7D819E-8C26-4D74-8683-4CED6903337EQ26738703-079BE381-AF82-4284-97BA-19D8EF42540CQ26752873-44A7033C-76FC-46E4-B4F2-7CFB66C5B457Q26773634-F579CCEB-F417-4CAE-A528-A7DA4B5F4999Q26777163-BF54A94D-B568-41DD-8F09-19971A423975Q26777310-ED4E7BA6-8D80-4611-BCD0-98B2BDC002F2Q26797063-712CA2DB-76E2-40B8-A1B4-5AE066DF87C1Q27008242-C464D016-1F53-443F-AF08-B29363D0A6C8Q28076745-E712274A-B364-4617-ACD7-C1C21D9C614DQ28078477-F43A3A40-A49F-4D39-98FA-9501C247744AQ28083261-58F993CF-EFB5-4394-B89D-3666833BBFC0Q28084943-E6AE5180-C8D9-45CF-BD12-481E66E32C8CQ28118861-2113C7FF-0B65-42F8-85C5-B04E48905D09Q28535386-224B54DF-C23E-46C7-A631-CF5DEC46AC69Q28593008-1B4C3784-06F4-4030-BDC2-48E82982A9BAQ28652074-77101FD8-6861-453F-9B98-72684A630CBAQ30439221-4BEA7F63-1F50-45AB-92D4-A982F5B4F375Q30479181-C2CED681-F60E-4263-B457-AD3CACD2EE2BQ30482634-976BD3CC-D589-4148-B260-3A618D944DB6Q30499412-65C6895E-DEC3-4BDA-AEFF-905A8A57D48EQ30500080-E405AD9A-7054-4032-8068-9BEAA3BB1341Q30643770-A9F51E94-2017-486C-943C-AB82C9457936Q33246793-5DD36D50-AF83-4051-8935-AB86686B1589Q33247276-99E60986-27E3-44B4-B9A3-AF6863607D0DQ33281964-D78DF18C-5169-4E12-A7C8-6746EA9CD12FQ33316388-6985A586-AD39-481A-910A-835C92B8DBFDQ33335942-868C4623-3ACD-4B79-84CC-C6CA7A0E1596Q33397762-2323F6FD-BFA8-4824-B9BF-F442AD90BD2EQ33471057-A9EB8CF2-B33E-4FE9-85DD-D2F69AB93BDDQ33586771-75171F2F-5C07-4554-9CEA-824A0B4EDCDB
P2860
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
description
article
@en
im Dezember 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2004
@uk
name
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@en
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@nl
type
label
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@en
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@nl
prefLabel
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@en
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
@nl
P2093
P50
P1433
P1476
Androgen-independent prostate ...... s from a rapid autopsy program
@en
P2093
Arul M Chinnaiyan
Debashis Ghosh
Gary R Macvicar
Jason Harwood
Rajal B Shah
Robert Kim
Rohit Mehra
Ronglai Shen
Tarek A Bismar
P304
P356
10.1158/0008-5472.CAN-04-2442
P407
P577
2004-12-01T00:00:00Z